Avalo Therapeutics (AVTX) announces the payoff of the remainder of its $35 million debt owed to Horizon Technology Finance Corporation (HRZN). This significant milestone not only signifies the company’s steadfast commitment to financial stability but also paves the way for future accelerated growth and progress toward executing its ambitious plans to advance its most promising drug candidates, including its anti-LIGHT mAb and its BTLA agonist fusion protein
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AVTX:
- Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation
- option delistings on September 25th
- Avalo Therapeutics enters into agreement to divest AVTX-800 series
- Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Avalo Therapeutics reports Q2 EPS (59c) vs ($1.38) last year
